SCHEMBL717259

SCHEMBL717259

CC(=O)N1CCN(c2nc3c(C)cccc3cc2C(C)N)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 7/20 0.53
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 4/20 0.45
TSHR P16473 2/20 0.44
USP2 O75604 1/20 0.44
CLK1 P49759 1/20 0.44
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
CNR2 P34972 1/20 0.41
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
THRB P10828 1/20 0.40
PKM P14618 1/20 0.40
KLK7 P49862 1/20 0.40
KMT2A Q03164 1/20 0.40
NCF1 P14598 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717258 1.00 PIK3CD (0.53) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL715529 0.87 MAPT (0.47) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL715528 0.87 MAPT (0.47) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL716672 0.86 PIK3CD (0.51) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL845236 0.84 ALOX15 (0.59) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL715736 0.84 ALOX15 (0.59) PIK3CDALDH1A1KDM4ETSHRUSP2
SCHEMBL715605 0.84 CNR2 (0.41) PIK3CDALDH1A1KDM4ECASP1CASP7
SCHEMBL715606 0.84 CNR2 (0.41) PIK3CDALDH1A1KDM4ECASP1CASP7
SCHEMBL2115701 0.82 NCF1 (0.49) PIK3CDALDH1A1KDM4ETSHRCASP1
SCHEMBL2115704 0.82 NCF1 (0.49) PIK3CDALDH1A1KDM4ETSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885ALDH1A1 3504/4885KDM4E 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.